NASDAQ:SPRO

Spero Therapeutics Stock Forecast, Price & News

Add
Compare
Today's Range N/A
50-Day Range
$13.03
$19.25
52-Week Range N/A
Volume411,885 shs
Average Volume164,845 shs
Market Capitalization$612.40 million
P/E RatioN/A
Dividend YieldN/A
Beta1.58

Receive SPRO News and Ratings via Email

Sign-up to receive the latest news and ratings for Spero Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Spero Therapeutics logo

About Spero Therapeutics

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant, or MDR, bacterial infections. Its pipeline product candidates include SPR994, SPR741, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.30 out of 5 stars

Medical Sector

249th out of 1,350 stocks

Pharmaceutical Preparations Industry

121st out of 664 stocks

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Spero Therapeutics (NASDAQ:SPRO) Frequently Asked Questions

Is Spero Therapeutics a buy right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Spero Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Spero Therapeutics stock.
View analyst ratings for Spero Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Spero Therapeutics?

Wall Street analysts have given Spero Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Spero Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Spero Therapeutics' next earnings date?

Spero Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, November 4th 2021.
View our earnings forecast for Spero Therapeutics
.

How were Spero Therapeutics' earnings last quarter?

Spero Therapeutics, Inc. (NASDAQ:SPRO) released its quarterly earnings results on Thursday, August, 5th. The company reported ($0.63) EPS for the quarter, beating the Zacks' consensus estimate of ($0.77) by $0.14. Spero Therapeutics had a negative net margin of 411.53% and a negative trailing twelve-month return on equity of 63.74%.
View Spero Therapeutics' earnings history
.

What price target have analysts set for SPRO?

4 brokers have issued twelve-month price targets for Spero Therapeutics' shares. Their forecasts range from $19.00 to $70.00. On average, they anticipate Spero Therapeutics' share price to reach $44.00 in the next year.
View analysts' price targets for Spero Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Spero Therapeutics' key executives?

Spero Therapeutics' management team includes the following people:
  • Ankit A. Mahadevia, President, Chief Executive Officer & Director
  • Cristina Larkin, Chief Operating Officer
  • Satyavrat Shukla, Treasurer, Chief Financial & Accounting Officer
  • Thomas R. Parr, Chief Scientific Officer
  • Troy Lister, Senior Vice President-Research & Development

What is Ankit Mahadevia, MD's approval rating as Spero Therapeutics' CEO?

27 employees have rated Spero Therapeutics CEO Ankit Mahadevia, MD on Glassdoor.com. Ankit Mahadevia, MD has an approval rating of 100% among Spero Therapeutics' employees. This puts Ankit Mahadevia, MD in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Spero Therapeutics' key competitors?

What other stocks do shareholders of Spero Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Spero Therapeutics investors own include Sorrento Therapeutics (SRNE), Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Editas Medicine (EDIT), SCYNEXIS (SCYX), (KDMN), Aldeyra Therapeutics (ALDX), KushCo (KSHB), Dynavax Technologies (DVAX) and Zosano Pharma (ZSAN).

When did Spero Therapeutics IPO?

(SPRO) raised $75 million in an IPO on Thursday, November 2nd 2017. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Cowen and Stifel served as the underwriters for the IPO and Oppenheimer & Co. was co-manager.

What is Spero Therapeutics' stock symbol?

Spero Therapeutics trades on the NASDAQ under the ticker symbol "SPRO."

Who are Spero Therapeutics' major shareholders?

Spero Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (5.53%), Vanguard Group Inc. (3.97%), State Street Corp (2.52%), Geode Capital Management LLC (1.29%), Dimensional Fund Advisors LP (1.16%) and Northern Trust Corp (0.81%). Company insiders that own Spero Therapeutics stock include Ankit Mahadevia, Aquilo Capital Management, Llc and Cristina Larkin.
View institutional ownership trends for Spero Therapeutics
.

Which institutional investors are selling Spero Therapeutics stock?

SPRO stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Goldman Sachs Group Inc., Morgan Stanley, Morgan Stanley, Citigroup Inc., Rafferty Asset Management LLC, Advisor Group Holdings Inc., and Russell Investments Group Ltd.. Company insiders that have sold Spero Therapeutics company stock in the last year include Ankit Mahadevia, Aquilo Capital Management, Llc, and Cristina Larkin.
View insider buying and selling activity for Spero Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Spero Therapeutics stock?

SPRO stock was bought by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Geode Capital Management LLC, JPMorgan Chase & Co., Dimensional Fund Advisors LP, Liberty Wealth Management LLC, Wells Fargo & Company MN, Northern Trust Corp, and ProShare Advisors LLC.
View insider buying and selling activity for Spero Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Spero Therapeutics?

Shares of SPRO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

How much money does Spero Therapeutics make?

Spero Therapeutics has a market capitalization of $0.00 and generates $9.33 million in revenue each year. The company earns $-78,280,000.00 in net income (profit) each year or ($3.52) on an earnings per share basis.

How many employees does Spero Therapeutics have?

Spero Therapeutics employs 89 workers across the globe.

What is Spero Therapeutics' official website?

The official website for Spero Therapeutics is sperotherapeutics.com.

Where are Spero Therapeutics' headquarters?

Spero Therapeutics is headquartered at 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139.

How can I contact Spero Therapeutics?

Spero Therapeutics' mailing address is 675 Massachusetts Avenue 14th Floor, Cambridge MA, 02139. The company can be reached via phone at (857) 242-1600 or via email at [email protected].


This page was last updated on 9/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.